Last reviewed · How we verify
Norepinephrine infusion
Norepinephrine infusion, marketed by Cairo University, is a well-established treatment in the pharmaceutical market. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity. The primary risk lies in potential competition once the patent expires, which could erode market share and revenue.
At a glance
| Generic name | Norepinephrine infusion |
|---|---|
| Also known as | Levophed, NORI |
| Sponsor | Cairo University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparing Two Different Norepinephrine Infusion Rates for Prophylaxis Against Spinal-induced Hypotension in Elderly (NA)
- Angiotensin II in Liver Transplantation (PHASE2, PHASE3)
- Vasopressor Impact on Brain Circulation, Organ Blood Flow and Tissue Oxygenation During Anesthesia (PHASE2, PHASE3)
- Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis (PHASE3)
- The GUARDIAN Pilot Trial (NA)
- Hand Perfusion and Pulse Oximetry Performance
- The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery (PHASE4)
- Dysfunctional Renin-Angiotensin System in Septic Shock (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Norepinephrine infusion CI brief — competitive landscape report
- Norepinephrine infusion updates RSS · CI watch RSS
- Cairo University portfolio CI